Regulus

Type: Keyphrase
Name: Regulus
First reported Oct 25 2014 - Updated Oct 25 2014 - 1 reports

Regulus extends gains

Regulus Therapeutics Inc. (Nasdaq: RGLS) extended its gains by soaring $2.79 to close at $17.33. ... [Published Chicago Daily Herald - Oct 25 2014]
First reported Oct 24 2014 - Updated Oct 24 2014 - 1 reports

Notable 52-Week Highs and Lows of the Day 10/24: (RGLS) (BJRI) (PG) High; (P) (HUBG) (FNFG) Low

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=9940383 for the full story.Related Stocks:BJ's Restaurants, Inc. EDWARDS LIFESCIENCES CORP First Niagara Financial Group HUB Group, Inc. PANDORA MEDIA, Inc. PROCTER & GAMBLE COMPANY ... [Published Nation's Restaurant News - Oct 24 2014]
First reported Oct 23 2014 - Updated Oct 24 2014 - 1 reports

3 Momentum Stocks to Watch in Biotechnology for Continued Upside

10/23/14 - 03:39 PM EDTNEW YORK ( TheStreet ) -- Wednesday was a strong session for a number of stocks, and here are three biotechnology  plays, in particular, to watch for more upside.Agios Pharmaceutical ( AGIO ) popped as high as $76.98 on Wednesday, ... [Published TheStreet.com - Oct 23 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

West Coast Biotech Roundup: Genentech, Sutro, Amgen, Regulus & More

Immunotherapy deals that could reach $1 billion? We’ve got two of them this week. Sure, those billion-dollar figures include, as they often do, a lot of biobucks, but the rest of the details in those deals—Genentech and NewLink Genetics; Celgene and Sutro ... [Published Xconomy - Oct 23 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Potential drug decreased viral load in patients with various HCV genotypes

Interim results from an ongoing clinical trial revealed that a microRNA therapeutic was well-tolerated and safe for the treatment of hepatitis C virus infection, according to a company release from Regulus Therapeutics.In the trial, currently taking place ... [Published Orthopedics Today - Oct 23 2014]
Entities: Genotype, RNA, Regulus
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Regulus Therapeutics' RG-101 Poses Liver Cancer Risk

Summary Wednesday Regulus Therapeutics announced that it has demonstrated human proof of concept with a microRNA therapeutic from an ongoing clinical study involving the drug's use for treatment of Hepatitis C. Targeting microRNA for the treatment of ... [Published Seeking Alpha - Oct 23 2014]
First reported Oct 22 2014 - Updated Oct 23 2014 - 1 reports

Markets Mostly Flat; Boeing Raises Earnings Forecast

Following the market opening Wednesday, the Dow traded up 0.04 percent to 16,622.06 while the NASDAQ fell 0.03 percent to 4,418.06. ...Related Stocks:3D SYSTEMS CORP BOEING COMPANY BOULDER BRANDS COEUR D'ALENE MINES CORP. COMPANHIA ENERGETICA COMPANHIA ... [Published Stock Nod - Oct 22 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Being an astronomy buff in cloudy Syracuse like 'being a surfer in Kansas'

Syracuse, N.Y. -- It looks like yet another astronomical event is going to be blotted out by clouds in Central New York.Tonight's partial solar eclipse just before sunset will likely be invisible to Central New Yorkers as a huge storm system parks over ... [Published Syracuse Online - Oct 23 2014]
First reported Oct 22 2014 - Updated Oct 23 2014 - 12 reports

Regulus Therapeutics: Gilead’s New Competitor?

Regulus Therapeutics released positive results for its hepatitis C drug candidate yesterday; Bidness Etc explores if the company can be a threat for GileadPage 1 of 2Click Ticker to See live coverageRegulus Therapeutics Inc ( RGLS ) exploded in the stock ... [Published Bidness Etc - Oct 23 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Strength Seen in Regulus (RGLS): Stock Soars 103.1%

(RGLS) was a big mover last session, as the company saw its shares surge over 103% on the day. The move came on solid volume with far more shares changing hands than in a normal session. Favorable early test data of a hepatitis C drug was primarily responsible ... [Published Yahoo! Finance - Oct 23 2014]
First reported Oct 22 2014 - Updated Oct 22 2014 - 3 reports

Regulus Hep C drug shows promise

Kleanthis Xanthopoulos, Regulus Therapeutics CEO and president, discusses the substantial reaction shown by a single dose of the company's Hepatitis-C drug. ... [Published CNBC - Oct 22 2014]
First reported Oct 22 2014 - Updated Oct 22 2014 - 1 reports

A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H

LA JOLLA, Calif., Oct. 22, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human ... [Published PR Newswire: General Business - Oct 22 2014]

Quotes

" Stanley Gibbons is paying £8.6m for the equity and the business brings net debt of £1.4m. This represents a discount to the stock value of £11.3mln" notes analyst Charles Hall
...that "RG-101 could not only be disruptive, but become the core treatment for hepatitis C to which direct anti-virals can be added," adding that "with these results, we anticipate Regulus is likely to receive widespread interest from potential partners for development and commercialisation." Regulus reportedly wants to start a mid-stage clinical trial in the second quarter of next year
Original Article: NEXT ARTICLE More From BioPortfolio on "Regulus Gets Seat at Hep C Table With Today's Impressive Drug Results"

More Content

All (132) | News (90) | Reports (0) | Blogs (40) | Audio/Video (0) | Fact Sheets (1) | Press Releases (1)
sort by: Date | Relevance
Regulus extends gains [Published Chicago Daily Herald - Oct 25 2014]
Notable 52-Week Highs and Lows of the Day 10/24... [Published Nation's Restaurant News - Oct 24 2014]
West Coast Biotech Roundup: Genentech, Sutro, A... [Published Xconomy - Oct 23 2014]
Potential drug decreased viral load in patients... [Published Orthopedics Today - Oct 23 2014]
3 Momentum Stocks to Watch in Biotechnology for... [Published TheStreet.com - Oct 23 2014]
Regulus Therapeutics' RG-101 Poses Liver Cancer... [Published Seeking Alpha - Oct 23 2014]
Being an astronomy buff in cloudy Syracuse like... [Published Syracuse Online - Oct 23 2014]
Reveal Insider Trading for Yahoo, 3D Systems, R... [Published BioSpace - Oct 23 2014]
Broker spotlight: Anglo American, Unilever, IAG... [Published Proactiveinvestors United Kingdom website - Oct 23 2014]
Broker spotlight: Anglo American, Unilever, IAG... [Published Proactiveinvestors United Kingdom RSS feed - Oct 23 2014]
Regulus Therapeutics: Gilead’s New Competitor? [Published Bidness Etc - Oct 23 2014]
Strength Seen in Regulus (RGLS): Stock Soars 10... [Published Yahoo! Finance - Oct 23 2014]
Promising hepatitis C drug = 100% gain [Published USA Today - Oct 23 2014]
Regulus Hep C drug shows promise [Published CNBC - Oct 22 2014]
This Stock Goes On Massive Tear Amid Positive H... [Published Benzinga.com - Oct 22 2014]
Why Regulus Therapeutics Inc. Stock More Than D... [Published Motley Fool Discussion Boards - Oct 22 2014]
Here’s Why Regulus Skyrocketed [Published Bidness Etc - Oct 22 2014]
Regulus Gets Seat at Hep C Table With Today's I... [Published Philly.com - Oct 22 2014]
Regulus surges on early hepatitis C drug data [Published FirstWord Pharma - Oct 22 2014]
Regulus surges on early hepatitis C drug data [Published Yahoo! Finance UK and Ireland - Oct 22 2014]
Regulus surges on early hepatitis C drug data [Published Street Sweeper - Oct 22 2014]
Regulus Gets Seat at Hep C Table With Today's I... [Published BioPortfolio - Oct 22 2014]
BioNews [10.22.14] [Published eClinical Trends - Oct 22 2014]
Regulus Gets Seat at Hep C Table With Today's I... [Published TheStreet.com - Oct 22 2014]
Regulus soars on promising--but early--results ... [Published FierceBiotech - Oct 22 2014]
Markets Mostly Flat; Boeing Raises Earnings For... [Published Stock Nod - Oct 22 2014]
Regulus Therapeutics Soars 90% On Hepatitis C T... [Published Benzinga.com - Oct 22 2014]
Regulus Therapeutics demonstrates human proof-o... [Published News-Medical.Net - Oct 22 2014]
Morning Buzz: Tekmira Pharmaceuticals (TKMR), B... [Published Wall Street Pit - Oct 22 2014]
A Single Subcutaneous Dose of 2mg/kg of RG-101,... [Published PR Newswire: General Business - Oct 22 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Broker spotlight: Anglo American, Unilever, IAG... [Published Proactiveinvestors United Kingdom website - Oct 23 2014]
JP Morgan has kept an underweight rating on mining titan Anglo American ( LON:AAL ), despite what it conceded was a solid third quarter trading update. Iron ore, copper and diamonds divisions were in line with or ahead of the broker’s forecast, but ...
BioNews [10.22.14] [Published eClinical Trends - Oct 22 2014]
Top News HeadlineCompanyType Gilead Sciences, Inc. $1,000-A-Pill Hepatitis C Drug May Make Financial Sense For Prisons Gilead Sciences, Inc.Hepatitis C Drug Regulus soars on promising–but early–results for its hep C contender Regulus T ...
A Single Subcutaneous Dose of 2mg/kg of RG-101,... [Published PR Newswire: General Business - Oct 22 2014]
LA JOLLA, Calif., Oct. 22, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human ...
Regulus Presents New Preclinical Data on Multip... [Published PR Newswire: Health - Oct 14 2014]
LA JOLLA, Calif., Oct. 14, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will present new preclinical ...
Regulus Announces $5 Million Financing [Published Marketwire - Breaking News Releases - Oct 14 2014]
CALGARY, ALBERTA--(Marketwired - Oct. 14, 2014) - Regulus Resources Inc. ("Regulus" or the "Company") (TSX VENTURE:REG) announces that it intends to raise up to $5 million through a non-brokered private placement (the " Financing ") consisting of ...
1 2 3 4 5 6 7 8

Press Releases

sort by: Date | Relevance
Google Executes $145 Million Investment In SunE... [Published Financial Services - Sep 10 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.